CL King Initiates Coverage On Silk Road Medical with Buy Rating, Announces Price Target of $47
Portfolio Pulse from richadhand@benzinga.com
CL King analyst Kristen Stewart initiates coverage on Silk Road Medical (NASDAQ:SILK) with a Buy rating and announces a price target of $47.
May 23, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silk Road Medical receives a Buy rating from CL King analyst Kristen Stewart, with a price target of $47.
The Buy rating and price target announcement by CL King analyst Kristen Stewart is a positive signal for Silk Road Medical. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100